Pillsbury acted as U.S. counsel to Meiji Seika Pharma Co., Ltd. on its expanded collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a messenger RNA medicines company, including a $50 million equity investment and an exclusive license agreement. Meiji provides pharmaceutical products, including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and hematologic disorders, and generic drugs.

Under the securities purchase agreement, Meiji will purchase Arcturus shares at $20.27 per share, representing approximately 7.9% of Arcturus’ outstanding shares following the transaction.

The exclusive license covers the application of Arcturus’ ARCT-154 technology in an undisclosed therapeutic area. The expanded collaboration also includes a memorandum of understanding outlining the principal terms of a potential collaboration and license agreement for a pandemic preparedness and response program in Japan.

Click here to learn more.

The Pillsbury deal team was led by Corporate partner Drew Simon-Rooke and included partners Richard Blaylock and Davina Kaile, counsels Brandon Eckford and Jeong Choi, and associates Lauryn Holliday and Nigel Frank; Executive Compensation & Benefits partner Mark Jones and associate Jack Donham; and International Trade partner Matthew Rabinowitz and counsel Roya Motazedi.